January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at Neurocrine Biosciences so special.

announces that in connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences , Inc. (“ Neurocrine Biosciences ”) announced 22 November 2021, the applicable waiting period completion of the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million, with the amount

June 2022 Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital age) and Adult (18 years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences , Inc.

December 2021 Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Food and Drug Administration in 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (

company Sosei Heptares has clinched a lucrative deal with California-based NASDAQ-quoted business Neurocrine Biosciences. Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878

Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization Morgan Healthcare Conference Neurocrine Biosciences, Inc.'s Director Stephen A.

2023 Thames Valley Tech Awards Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results Neurocrine Biosciences Announces Appointment of Christine A.

News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes Dr.

Recipient of a Highly Competitive European Grant to Fund Drug Development and Reports Financing Highlights Neurocrine Biosciences Provides Development Pipeline Update Crinetics Pharmaceuticals Announces November 2023 Inducement immune characteristics of the microenvironment and the process of EBV-induced lymphomagenesis Tanso Biosciences

Industry News Trevena Announces Publication of OLINVYK Respiratory Physiology Study In Anesthesiology Neurocrine Biosciences discovers new muscarinic M4 receptor antagonists Alexander S.

Consolidated Results for the Second Quarter and First Half 2024 Cracking Codes in Cellular Communication Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference GPCR drugs make up a third

discovery of GPCR signaling Illuminating the understudied GPCR-ome Industry News Sosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical

Models Probing the energy landscape of the lipid interactions of the serotonin1A receptor Industry News Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results G-Protein

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results Novel full

Investment Summit BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations

Collaboration with Charité to Advance Development of Precision Medicine Platform Sosei Heptares and Neurocrine Biosciences won Top Out-Licensing Deal on the 8th annual Japan Deal of the Year Call for GPCR Papers

upfront to give solid tumor CAR-T the T-Charge treatment Innovation And Healthcare Meet At Novartis Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PostEra

72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results

structure determination GPCR-G protein selectivity revealed by structural pharmacology Industry News Neurocrine Biosciences Announces U.S.

Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust

its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation

Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings Neurocrine Biosciences

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID --(BUSINESS WIRE)--Nov. 15, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers develop and commercialize an antibody, discovered and optimized by Twist Biopharma, a division of Twist Bioscience

Aaron Sato , Chief Scientific Officer at Twist Bioscience , elaborates.

clocked in at $1 billion—with Genentech—and, just last November, $2.6 billion in a partnership with Neurocrine

1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study Neurocrine